SAGE Therapeutics Inc (NASDAQ:SAGE) – Stock analysts at Oppenheimer decreased their FY2022 EPS estimates for shares of SAGE Therapeutics in a note issued to investors on Tuesday, November 20th. Oppenheimer analyst J. Olson now expects that the biopharmaceutical company will earn $0.97 per share for the year, down from their prior forecast of $0.99. Oppenheimer currently has a “Buy” rating and a $170.00 target price on the stock.
SAGE Therapeutics (NASDAQ:SAGE) last released its quarterly earnings data on Tuesday, November 6th. The biopharmaceutical company reported ($2.63) earnings per share for the quarter, missing the consensus estimate of ($2.41) by ($0.22). During the same quarter in the prior year, the company posted ($1.97) earnings per share.
SAGE stock opened at $111.78 on Thursday. SAGE Therapeutics has a 1-year low of $88.03 and a 1-year high of $195.97. The company has a market capitalization of $5.08 billion, a PE ratio of -15.77 and a beta of 2.76.
Hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Flinton Capital Management LLC grew its position in SAGE Therapeutics by 1,900.0% during the 2nd quarter. Flinton Capital Management LLC now owns 680 shares of the biopharmaceutical company’s stock worth $106,000 after acquiring an additional 646 shares during the last quarter. US Bancorp DE grew its position in SAGE Therapeutics by 5,593.3% during the 2nd quarter. US Bancorp DE now owns 854 shares of the biopharmaceutical company’s stock worth $133,000 after acquiring an additional 839 shares during the last quarter. Creative Planning bought a new stake in SAGE Therapeutics during the 2nd quarter worth approximately $210,000. Atria Investments LLC bought a new stake in SAGE Therapeutics during the 2nd quarter worth approximately $218,000. Finally, Tiverton Asset Management LLC acquired a new position in SAGE Therapeutics during the 2nd quarter worth $229,000.
About SAGE Therapeutics
Sage Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops and commercializes novel medicines to treat central nervous system disorders. Its lead product candidate comprises brexanolone, a proprietary intravenous formulation of allopregnanolone that has completed III clinical trials for the treatment of post-partum depression (PPD).
Receive News & Ratings for SAGE Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for SAGE Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.